| Name | Title | Contact Details |
|---|---|---|
Justin McCue |
Chief Technology Officer | Profile |
CERN Foundation is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ElevateBio is accelerating the future of biotechnology. We have a launched a revolutionary new model that integrates innovators, infrastructure and capital to effectively develop cell, gene and related therapies for patients with severe and life-threatening disorders.
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle. Sapacitabine (CYC682), Cyclacel`s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel`s pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including BRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor in a Phase 1 study of patients with solid tumors with potential utility in both hematological malignancies and solid tumors. Cyclacel`s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Cyclacel Pharmaceuticals` corporate headquarters are in Berkeley Heights, New Jersey, where our business development and medical and regulatory functions are also located. The company`s primary research facility is located in Dundee, Scotland. Dundee is the main location of our translational research and preclinical activities.
Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.